Used in the treatment of moderate to severe systemic lupus erythematosus (SLE), this antibody targets the type I interferon receptor, blocking the signaling of interferons that contribute to autoimmune activity. By inhibiting this pathway, it helps reduce disease activity, including skin and joint symptoms, and decreases the likelihood of flare-ups. It is administered intravenously and is particularly beneficial for patients who have not responded adequately to standard therapies. Its use is supported by clinical trials showing improved outcomes in seropositive patients with high interferon signatures.